Agomab Therapeutics Reports Positive Phase 1 Data for Lung Disease Drug
By Elias SchisgallAgomab Therapeutics said a phase 1 study for a lung disease treatment showed a reduction in a target protein, supporting the launch of a phase 2 study.The clinical-stage biopharmaceutical company said that a twice-daily 4.5mg dose of AGMB-447, a treatment for idiopathic pulmonary…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.